GSK to bolster its ability to develop and market vaccines

Pharma giant's vaccine chief vows to step up its activity in the 'crown jewel' of its business 

GSK is focusing more on vaccine production.

GlaxoSmithKline fell behind in the Covid-19 vaccine race, but now the drugmaker is working to make sure it is on the front lines of the next pandemic.

The pharma giant is talking with the UK and other governments about building facilities to bring vaccine development and production onshore before the next crisis, said Roger Connor, its vaccines chief.